These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7127320)

  • 1. Augmentation of the human immune response by cyclophosphamide.
    Berd D; Mastrangelo MJ; Engstrom PF; Paul A; Maguire H
    Cancer Res; 1982 Nov; 42(11):4862-6. PubMed ID: 7127320
    [No Abstract]   [Full Text] [Related]  

  • 2. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide.
    Berd D; Maguire HC; Mastrangelo MJ
    Cancer Res; 1984 Nov; 44(11):5439-43. PubMed ID: 6488195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 study of intermittent high-dose cyclophosphamide therapy of advanced gastrointestinal cancer.
    Schutt AJ; Hahn RG; Reitemeier RJ; Moertel CG
    Cancer Res; 1973 Oct; 33(10):2218-20. PubMed ID: 4741927
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of cyclophosphamide and cytarabine in the treatment of metastatic adenocarcinoma of the colon and rectum.
    Denefrio JM; Kaplan RS; Eisenberger MA; Lessner HE
    Cancer Treat Rep; 1981; 65(1-2):163-4. PubMed ID: 7226166
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea adjuvant therapy on the immune response of patients with malignant melanoma.
    Berd D; Wilson EJ; Bellet RE; Mastrangelo MJ
    Cancer Res; 1979 Nov; 39(11):4472-6. PubMed ID: 387215
    [No Abstract]   [Full Text] [Related]  

  • 6. Low dosage methotrexate (NSC-740) and cyclophosphamide (NSC 26271) for solid tumors.
    Foley JF; Lemon HM; Miller D
    Cancer Chemother Rep; 1970 Feb; 54(1):41-6. PubMed ID: 4334084
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunotherapy of human solid tumors with Bacillus Calmette-Guérin: prolongation of disease-free interval and survival in malignant melanoma, breast, and colorectal cancer.
    Gutterman JU; Mavligit GM; Blumenshein G; Burgess MA; McBride CM; Hersh EM
    Ann N Y Acad Sci; 1976; 277(00):135-59. PubMed ID: 1069546
    [No Abstract]   [Full Text] [Related]  

  • 8. Tumor spread and reactivity to DNCB: (2, 4 Dinitro-1 chlorobenzene) skin test.
    el-Domeiri AA
    Int Surg; 1972 Aug; 57(8):617-9. PubMed ID: 5051760
    [No Abstract]   [Full Text] [Related]  

  • 9. Phase II trial of bisantrene in advanced colorectal carcinoma.
    Ahmed T; Kemeny NE; Michaelson RA; Harper HD
    Cancer Treat Rep; 1983 Mar; 67(3):307-8. PubMed ID: 6831479
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase II trial: mitomycin c and methotrexate combination therapy for advanced colorectal carcinoma.
    Budman DR; Schulman P; Vinciguerra V; Degnan T
    Cancer Treat Rep; 1981; 65(5-6):535. PubMed ID: 7237477
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclosporine delays host immune response to antibody enzyme conjugate in ADEPT.
    Bagshawe KD; Sharma SK
    Transplant Proc; 1996 Dec; 28(6):3156-8. PubMed ID: 8962223
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II evaluation of metoprine in patients with advanced colorectal carcinoma.
    Lynch G; Kemeny N; Currie V
    Cancer Treat Rep; 1981; 65(1-2):127-8. PubMed ID: 7226162
    [No Abstract]   [Full Text] [Related]  

  • 13. Delayed hypersensitivity in cancer patients: cutaneous and in vitro lymphocyte response to specific antigens.
    Nelson HS
    J Natl Cancer Inst; 1969 May; 42(5):765-70. PubMed ID: 5797546
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunologic testing as a guide to cancer management.
    Wanebo HJ
    Surg Clin North Am; 1979 Apr; 59(2):323-47. PubMed ID: 375447
    [No Abstract]   [Full Text] [Related]  

  • 15. [Advantages and disadvantages of high-dosed intensive chemotherapeutic treatment of malignant tumor formations].
    Bock HE; Allner R; Gross R
    Dtsch Med Wochenschr; 1967 Apr; 92(14):641-6. PubMed ID: 6024537
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy of malignant melanoma with vaccinia virus.
    Roenigk HH; Deodhar S; St Jacques R; Burdick K
    Arch Dermatol; 1974 May; 109(5):668-73. PubMed ID: 4828533
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoclonal antibodies to human tumor antigens.
    Steplewski Z
    Transplant Proc; 1980 Sep; 12(3):384-7. PubMed ID: 7222217
    [No Abstract]   [Full Text] [Related]  

  • 18. [Increased cancer risk after appendectomy from the immunologic view].
    Breucha G; Saal JG; Kieninger G
    Med Welt; 1982 Feb; 33(8):289-93. PubMed ID: 7078395
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of the dose and composition of an autologous hapten-modified melanoma vaccine on the development of delayed-type hypersensitivity responses.
    Berd D; Sato T; Mastrangelo MJ
    Cancer Immunol Immunother; 2002 Aug; 51(6):320-6. PubMed ID: 12111120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunopotentiation by pyrimethamine in the mouse.
    Thong YH; Ferrante A
    Clin Exp Immunol; 1980 Jan; 39(1):190-4. PubMed ID: 7389192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.